secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001493152-23-016686
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences Q1 2023 revenue $9.8M, up 24% YoY; turns profitable
-------------------------------------------------------------------------

- Net revenue $9.8M (+24% YoY); test volume up ~20% to record levels.
- Income from continuing ops $0.4M vs loss of $1.1M; operating income $0.7M vs loss $1.0M.
- Adjusted EBITDA $1.2M vs -$0.3M; cash balance $5.6M vs $2.9M a year ago.
- Added 41.9M covered lives via 8 new/updated commercial contracts in Q1.
- Gross profit margin improved to 61% from 59% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223016686/0001493152-23-016686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223016686/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer